New law allows Demecan to grow more cannabis

Production restrictions no longer apply

The three companies had won a corresponding tender from the Federal Institute for Drugs and Medical Devices (BfArM) in 2019. However, under the old regulation, only a certain amount of cannabis could be cultivated. In total, the tender stipulated that the three companies would produce a good ten tons over four years. In addition, the cannabis grown in Germany could only be sold to pharmacies via the state cannabis agency. With the new law, companies will now be spared this intermediate step.

According to Demecan, the approval is "crucial to meet the growing demand for medical cannabis and to turn the tide in supply by shifting the focus from imports to more domestic production". "Our goal is to further increase production and thus improve the security of supply, because unfortunately there are currently many bottlenecks in patient care," said Adrian Fischer, one of the managing directors.